The Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial (Ridker et al., 2008, 2010), have reported the role of CRP as a biomarker of risk for cardiovascular disease and established it as a means of monitoring the impact of cholesterol-lowering therapy, not only in people with known risks, but also in asymptomatic individuals previously considered at average risk for myocardial infarction and stroke. The gene discussed is CRP; the disease is myocardial infarction.